Stuttgart - Delayed Quote EUR

Medigene AG (MDG1.SG)

0.1075

-0.0030

(-2.71%)

As of 2:30:03 PM GMT+2. Market Open.

Medigene Files Patent for Unique NK-Specific TCR Construct with European Patent Office

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the submission of a patent for a novel natural killer (NK) cell-specific TCR construct to the European Patent Office. With that, Medigene is advancing its TCR-guided strategy by expanding the application of its proprietary 3S (sensitive, specific, and safe) TCRs into NK cells. This patent app

GlobeNewswire 2 months ago

MDGEF
Medigene and EpimAb to develop T cell engagers for solid tumours

The joint effort aims to produce TCR-TCE constructs, with ownership shared equally between the two companies.

Pharmaceutical Technology 2 months ago

MDG1.DE
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers

EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop off-the-shelf T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of immune-related disorders, such as solid tumors. The multi-target collaboration combines the respective expertise of each company with Medigene’s 3S (

GlobeNewswire 2 months ago

MDGEF
Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.

Planegg/Martinsried, February 19, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced today that the Company has been issued a patent by the U.S. Patent Office protecting its JOVI technology, a method allowing the enrichment of T cells using a specific anti-Cβ antibody. The U.S. patent for the JOVI technology was granted at the end of last ye

GlobeNewswire 2 months ago

MDGEF
Medigene AG announces closing of its first SEPA tranche

Planegg/Martinsried, February 3, 2025. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced the closing of its first tranche of the Standby Equity Purchase Agreement (“SEPA”) with a fund managed by Yorkville Advisors Global, LP (“Yorkville”) announced on January 24, 2024. The subscription price was set at EUR 1.70 and is equal to 95%

GlobeNewswire 3 months ago

MDGEF
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers

Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the selection of Kirsten rat sarcoma viral oncogene homologue (KRAS) G12V, in the context of HLA*A11, as the initial target for the co-development of T cell receptor-guided T cell engagers (TCR-TCEs) with WuXi Biologics. The selection of

GlobeNewswire 5 months ago

MDGEF
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.

Payment triggered by development milestone achieved by Regeneron’s collaborator in China, JW TherapeuticsProgresses first clinical use of Medigene’s End-to-End Platform to generate potentially best-in-class TCRs Planegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced a USD $1 million mileston

GlobeNewswire 5 months ago

MDGEF
Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment

Planegg/Martinsried, November 26, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced today an update of its corporate strategy to refocus its capital allocation on R&D programs with highest potential for return on invested capital resulting in an organizational realignment. This strategic refocus supports the Company’s short-, mid-, and long-

GlobeNewswire 5 months ago

MDGEF
Medigene Presents Data on an Innovative IFN-γ Biosensor Technology at SITC 2024

Planegg/Martinsried, November 12, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, presented data on the newest addition to its End-to-End (E2E) Platform, an Interferon-Gamma (IFN-γ) Biosensor technology that allows real-time monitoring and quantification of IFN-γ release from cytokine-secreting cells at the Society of Immunotherapy

GlobeNewswire 5 months ago

MDGEF
Medigene Presents Latest Data on UniTope & TraCR Technology at PEGS and SITC 2024

Planegg/Martinsried, November 11, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, presented latest updates on its End-to-End (E2E) Platform technology - the UniTope and TraCR technology, a universal detection system for tagging and tracking recombinant TCRs (rTCRs), at the Protein & Antibody Engineering Summit (PEGS) in Barcelona fr

GlobeNewswire 6 months ago

MDGEF
Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024

Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & DevelopmentPresentations and seminars highlighted Medigene’s proprietary End-to-End Platform for generation of extraordinary T cell receptors for application in various modalities and overview of the lead TCR-T therapy program MDG1015 Planegg/Martinsried, November 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard),

GlobeNewswire 6 months ago

MDGEF
Can Medigene (ETR:MDG1) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 6 months ago

MDGEF
Medigene to Present at Upcoming Investor Conferences

Planegg/Martinsried, October 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will attend BIO-Europe from November 4-6, 2024 in Stockholm as well as at the Investival Showcase Biotech, Heathcare, Medtech conference on November 18, 2024 in London. In addition, the Company will present at the Deutsches Eigenkapitalforum from Novemb

GlobeNewswire 6 months ago

MDGEF
Medigene AG reports Financial Results and Business Update for Q3 2024

Planegg/Martinsried, October 24, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today reported financial results and provided a business update for the third quarter ended September 30, 2024. The Quarterly Statement Q3 2024 can be found on the website: https://medigene.com/investors-media/reports-presentations/. "During the third q

GlobeNewswire 6 months ago

MDGEF
Medigene presents UniTope and TraCR a universal detection system for 3S recombinant TCRs at ASGCT 2024

Planegg/Martinsried, October 17, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, presented a universal detection system for 3S (specific, sensitive, and safe) recombinant TCRs (rTCRs), UniTope & TraCR, at the American Society of Gene & Cell Therapy (ASGCT) to be held October 16-17, 2024 in Philadelphia, PA in the US. The presented p

GlobeNewswire 6 months ago

MDGEF
Medigene to Present at Upcoming Scientific Conferences

Planegg/Martinsried, October 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will present at the 16th Annual Protein & Antibody Engineering Summit (PEGS) to be held from November 5-7, 2024 in Barcelona as well as at the Cell 2024 conference by Oxford Global from November 6-8, 2024 in London. In addition, two posters will be pres

GlobeNewswire 6 months ago

MDGEF
Medigene will Present at ASGCT 2024 and Host R&D Event

Planegg/Martinsried, October 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will present a poster at the American Society of Gene & Cell Therapy (ASGCT) to be held October 16-17, 2024 in Philadelphia, PA in the US. In addition, the Company will host an R&D Event on Medigene’s optimal 3S (specific, sensitive, and safe) TCRs for T

GlobeNewswire 7 months ago

MDGEF
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021

Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the filing of a new patent application protecting MDG2021, a T cell receptor engineered T cell (TCR-T) therapy targeting Kirsten rat sarcoma viral oncogene homologue (KRAS) G12D with human leukocyte antigen (HLA)-A*11, for the TCR-T t

GlobeNewswire 7 months ago

MDGED
Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies

Planegg/Martinsried, September 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will host an R&D Event on Medigene’s optimal 3S (specific, sensitive, and safe) TCRs for TCR-guided precision immunotherapies on Thursday, October 10, 2024, at 4.30 pm CET / 10:30 am ET. A live Q&A session will follow the formal presentations and disc

GlobeNewswire 7 months ago

MDGED
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, presented updates for its T cell receptor (TCR) library targeting the Kirsten rat sarcoma viral oncogene homolog (KRAS) and also highlighted advancements of its UniTope and TraCR technology, which serves as a universal system for tagging and tracking

GlobeNewswire 7 months ago

MDGED

Performance Overview

Return	MDG1.SG	DAX P (^GDAXI)
YTD	-94.73%	+19.44%
1-Year	-96.23%	+26.90%
3-Year	-97.91%	+70.28%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Medigene AG (MDG1.SG)

Medigene Files Patent for Unique NK-Specific TCR Construct with European Patent Office

Medigene and EpimAb to develop T cell engagers for solid tumours

Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers

Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.

Medigene AG announces closing of its first SEPA tranche

Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers

Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.

Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment

Medigene Presents Data on an Innovative IFN-γ Biosensor Technology at SITC 2024

Medigene Presents Latest Data on UniTope & TraCR Technology at PEGS and SITC 2024

Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024

Can Medigene (ETR:MDG1) Afford To Invest In Growth?

Medigene to Present at Upcoming Investor Conferences

Medigene AG reports Financial Results and Business Update for Q3 2024

Medigene presents UniTope and TraCR a universal detection system for 3S recombinant TCRs at ASGCT 2024

Medigene to Present at Upcoming Scientific Conferences

Medigene will Present at ASGCT 2024 and Host R&D Event

Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021

Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies

Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

Performance Overview